Stock FRBN.U FORBION EUROPEAN ACQUISITION CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Forbion European Acquisition Corp. Share Price Nasdaq

Equities

FRBN.U

KYG3619H1285

Financials

Sales 2021 - Sales 2022 - Capitalization 163M 13.61B
Net income 2021 - 0 Net income 2022 - 0 EV / Sales 2021 * -
Net cash position 2021 1.07M 89.12M Net cash position 2022 314K 26.18M EV / Sales 2022 -
P/E ratio 2021 *
-
P/E ratio 2022
5,317 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 0%
More Fundamentals * Assessed data

Chart Forbion European Acquisition Corp.

Dynamic Chart

Latest news about Forbion European Acquisition Corp.

EnGene, Inc. completed the acquisition of Forbion European Acquisition Corp. from a group of shareholders in a reverse merger transaction. CI
Forbion European Acquisition Corp.(NasdaqGM:FRBN) dropped from NASDAQ Composite Index CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting MT
Forbion European Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast MT
Top Premarket Decliners MT
Forbion European Acquisition Corp. announced that it has received $1.265 million in funding CI
Forbion European Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Forbion European Acquisition Corp. announced that it has received $1.265 million in funding from Forbion Growth Sponsor Feac I B.V. CI
Forbion European Acquisition Corp. entered into a business combination agreement to acquire enGene, Inc from shareholders. CI
Forbion European Acquisition Corp. announced that it has received $56.891682 million in funding from a group of investors CI
Forbion European Acquisition Corp. announced that it received $56.891682 million in funding from enGene Holdings, and other investors CI
Forbion European Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Forbion European Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Forbion European Acquisition Corp. Auditor Raises 'Going Concern' Doubt CI
More news

Press releases Forbion European Acquisition Corp.

EnGene, Inc. and Forbion European Acquisition Corp. ("FEAC", Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies - Form 8-K PU
More press releases

Company Profile

Forbion European Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination. The Company intend to focus its search on lifestyle, technology, healthcare and wellness sectors. The Company has not commenced any operations nor generated any revenue.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. FRBN Stock
  4. FRBN.U Stock